Inogen Taps Veteran COO Andy Reding to Steer Growth and Operational Pivot

BEVERLY, Mass. – July 01, 2026 – In a strategic move signaling a sharpened focus on execution and growth, medical technology firm Inogen, Inc. (Nasdaq: INGN) has appointed Andy Reding to the newly created role of Chief Operating Officer. The appointment, effective July 6, 2026, places a seasoned industry veteran at the operational helm as the company navigates a period of product diversification and global expansion.

Reding will be tasked with driving revenue, optimizing operational performance, and aligning cross-functional priorities. The creation of the COO position itself speaks volumes about the company's current trajectory, suggesting a deliberate effort to tighten execution as it scales. Inogen, a key player in innovative respiratory products for homecare, is looking to translate its strategic plans into more efficient and measurable outcomes.

“As we continue to diversify Inogen’s business through new product launches and geographic expansion, we are streamlining our leadership structure to enhance execution and accelerate delivery of our strategic priorities,” said Kevin Smith, Inogen’s Chief Executive Officer. “Andy’s deep experience building high-performing teams and scaling complex medical technology businesses will be invaluable as we continue to drive top-line growth, advance profitability and expand the innovation pipeline.”

A Strategic Move for Growth and Efficiency

The timing of Reding’s appointment is critical. While Inogen reported better-than-expected Q1 2026 revenue of $85.1 million—a 3.4% increase year-over-year driven by strong international demand—the company also saw its GAAP net loss widen to $8.3 million from $6.2 million in the prior-year period. This financial picture, one of modest top-line growth coupled with profitability pressures, underscores the need for a leader focused squarely on operational excellence.

The company has reiterated its full-year 2026 revenue guidance of $366 million to $373 million, representing approximately 6% growth at the midpoint. More importantly, it remains committed to improving its adjusted EBITDA. Achieving these targets requires not just selling more products, but doing so more efficiently. Reding's mandate appears directly aimed at this challenge: to build a more robust operational engine capable of supporting Inogen's ambitions for sustained long-term growth and profitability.

His role will be pivotal in coordinating the company’s strategic initiatives, which include expanding its domestic provider networks, increasing international business-to-business adoption of its portable oxygen concentrators (POCs), and optimizing its direct-to-consumer sales channels. By creating a central operational authority, Inogen aims to ensure these disparate efforts are harmonized for maximum impact.

Tapping Deep Respiratory and Commercial Expertise

For a company competing in the specialized field of respiratory care, Reding's resume is particularly compelling. With over 30 years in medical technology, his experience is not just broad but deeply relevant. He joins Inogen from Viant Medical, where he served for over six years as Chief Commercial Officer. At Viant, he led teams supporting complex medical-device design and manufacturing programs across 25 facilities, serving some of the world's top med-tech companies and overseeing a period of exceptional growth.

Even more pertinent is his tenure as Vice President and General Manager of Hillrom Respiratory Health. In that role, Reding was directly responsible for a division focused on respiratory care, leading sales, marketing, R&D, and reimbursement. His experience in expanding sales forces, developing new products, and successfully navigating the intricate regulatory requirements of the FDA and CMS is a direct match for the challenges and opportunities Inogen faces today. This background provides him with a unique, ground-level understanding of the product development lifecycle and commercialization path in the respiratory market.

“I am honored to join Inogen at such an important time in the company’s evolution,” said Reding in the company’s official announcement. “Inogen has a strong foundation, a compelling mission, and significant opportunities to expand its impact for patients and providers globally. I look forward to working with Kevin and the broader team to transform Inogen into a global respiratory care leader.”

Navigating a Competitive Landscape

Inogen operates in a dynamic and competitive market. Its innovative products, such as the Inogen Rove series of POCs and the Voxi stationary concentrator, are designed to offer patients greater freedom and mobility. However, the company faces persistent competition, evolving reimbursement landscapes, and the constant need to prove the clinical and economic value of its technology. Reding's appointment is a clear investment in strengthening the company's ability to execute within this environment.

His experience in scaling manufacturing and commercial operations at Viant will be critical as Inogen pushes for greater market penetration both in the U.S. and abroad. Furthermore, his leadership in R&D and product launches at Hillrom suggests he is well-equipped to help guide Inogen's innovation pipeline, ensuring that new products not only meet patient needs but also clear regulatory hurdles and achieve commercial success. This blend of operational, commercial, and technical expertise is precisely what a company at Inogen's inflection point requires.

An Inducement to Drive Long-Term Value

To attract a leader of Reding’s caliber, Inogen has put forth a significant compensation package, underscoring the strategic importance of the new COO role. In addition to a $500,000 base salary and a target bonus of 70%, he will receive a one-time cash sign-on bonus of $100,000.

More significantly, the package includes an inducement equity award of 130,000 restricted stock units (RSUs), which will vest in equal installments over three years. This grant was made under Nasdaq Listing Rule 5635(c)(4), a provision that allows companies to issue equity to new employees as a material inducement to employment without requiring shareholder approval. This common tool for attracting top-tier executive talent is designed to align the long-term interests of the new leader with those of shareholders.

By tying a substantial portion of Reding’s compensation to the company's stock performance over the next three years, Inogen's board is creating a powerful incentive for him to deliver on his mandate. His success in driving revenue, improving profitability, and streamlining operations will now be directly linked to his own financial outcomes, a classic governance move to ensure executive focus is squarely on creating shareholder value as Inogen embarks on its next chapter of growth.